This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|October 16, 2019
Sanofi Opens New Digital Manufacturing Facility in Massachusetts
Author(s)BioPharm International Editors
The new location is one of the world’s first digital facilities to use intensified, continuous biologics production technology.
Advertisement
Sanofi announced the opening of its new digital manufacturing facility in Framingham, MA, on Oct. 15, 2019. The new location is one of the world’s first digital facilities to use intensified, continuous biologics production technology, according to a company press release.
According to Sanofi, the new facility is 80 times more productive and will make medicines for two times the number of patients per year than a traditional factory, using technology that connects the production process with R&D. By utilizing paperless and single-use manufacturing technologies to replace the large-scale fixed stainless-steel equipment, the company’s carbon footprint is reduced with less CO2 emissions.
Additionally, the new location has the ability to quickly change from one manufacturing process to another, enabling the factory to manufacture biologics for the company’s Genzyme portfolio.
The facility is part of the company’s Framingham campus, a global hub for medicines that has been active for 30 years. The company has invested
"We have been investing for some years to prepare for Sanofi's future. Our Framingham facility leads the way in delivering the next generation of biologics manufacturing, leveraging intensified, continuous processing in a fully integrated digitally powered facility," said Philippe Luscan, executive vice-president, Global Industrial Affairs at Sanofi, in the press release. "This opening demonstrates we are at the leading edge of innovation and manufacturing excellence, helping us to shape the future of both our company and the industry."
Sanofi plans to continue to expand its digital transformation initiatives in Canada, Brazil, Ireland, France, and Belgium.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5